Compare TELA & NMTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TELA | NMTC |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.7M | 41.0M |
| IPO Year | 2019 | 2010 |
| Metric | TELA | NMTC |
|---|---|---|
| Price | $0.70 | $0.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $3.31 | $2.23 |
| AVG Volume (30 Days) | ★ 334.2K | 232.6K |
| Earning Date | 02-24-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 34.80 | ★ 80.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $69,300,000.00 | $9,097,692.00 |
| Revenue This Year | $18.41 | N/A |
| Revenue Next Year | $15.20 | $32.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 18.56 | ★ 163.47 |
| 52 Week Low | $0.67 | $0.40 |
| 52 Week High | $2.73 | $1.18 |
| Indicator | TELA | NMTC |
|---|---|---|
| Relative Strength Index (RSI) | 33.21 | 39.12 |
| Support Level | $0.75 | $0.66 |
| Resistance Level | $0.80 | $0.86 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 16.88 | 9.95 |
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.